Clinical Approaches to Targeted Technologies: Implementing the Promise of Prognostic Precision Into Personalized Cancer Care

Interactive Learning
Roy S. Herbst, MD, PhD
Leonard Saltz, MD
Lisa Carey, MD
Oliver Sartor, MD

Valid: November 29th, 2012 - November 29th, 2013

Program Overview
Until recently, cancer treatment relied solely on histologic diagnosis for determining systemic therapy. Aside from considerations related to a patient’s underlying comorbidities and performance status, there was minimal deviation from an organ-of-origin-based treatment strategy.

Current molecular targets include cell-surface receptors, mediators of intracellular signaling, and regulators of cellular processes such as DNA repair. Moreover, new molecular biomarkers are being discovered and validated that hold the potential for optimizing treatment decisions for solid tumors.

Thus, a significant need exists for healthcare professionals who manage patients with cancer to keep abreast of the latest information on tumor biomarkers and how to appropriately use them to optimize therapy for their patients.

Learning Objectives
Upon completion of this educational activity, participants were able to:

  • Assess emerging data and recent advances in the discovery of solid tumor biomarkers, their impact on the treatment of patients with solid tumors, and how to integrate key findings into clinical practice
  • Discuss the role of tumor biomarkers in designing personalized therapy for patients with solid tumor cancers, including management of treatment-related adverse events

Agenda
Welcome/Agenda Review

Roy S. Herbst, MD, PhD

Overview of the Current State of Solid Tumor Biomarkers
Roy S. Herbst, MD, PhD

Latest Clinical Data on Molecular Biomarkers and Their Impact on the Management of Patients with Solid Tumors
Lisa Carey, MD; Leonard B. Saltz, MD; Oliver Sartor, MD

Case Studies: Challenges/Issues in Everyday Practice (with ARS component)
Roy S. Herbst, MD, PhD; Lisa Carey, MD; Leonard B. Saltz, MD; Oliver Sartor, MD

Future Directions in Personalized Medicine and Tumor Biomarkers
Roy S. Herbst, MD, PhD

Q & A and Panel Discussion

Roy S. Herbst, MD, PhD (Chair)
Professor of Medicine & Pharmacology
Chief of Medical Oncology
Director, Thoracic Oncology Research Program
Associate Director for Translational Research
Translational Research Program
Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, CT

Roy S. Herbst, MD, PhD discloses that he receives Grant Support/Research Funding from Genentech, , BMS, GSK,; Paid Consultant/Honoraria: Genentech, Argennix Inc, Allos Therapeutics, Ingelhim,; Scientific Advisory Boards: Biotheria, Genetics Squred, MedTrust, N of One, SynDev Rx, Targeted Molecular Diagnostics, DiaTech.  He does not intend to discuss non–FDA-approved or investigational use for products/devices.

Lisa Carey, MD
Preyer Distinguished Professor in Breast Cancer Research
Professor of Medicine
Medical Director, UNC Breast Cancer Center
Associate Director, Clinical Research
UNC Lineberger Comprehensive Cancer Center
University of North Carolina School of Medicine
Chapel Hill, NC

Lisa Carey, MD, has nothing to disclose. She intends to discuss non–FDA-approved or investigational use for products/devices.

Leonard B. Saltz, MD
Professor of Medicine
Chief, Gastrointestinal Oncology
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, NY

Leonard B. Saltz, MD, discloses that he is a consultant for Asuragen, Bristol-Myers Squibb, Genzyme, Genentech, Genomic Health, ImClone, and Roche. He does not intend to discuss non–FDA-approved or investigational use for products/devices.

Oliver Sartor, MD
Medical Director, Tulane Cancer Center
Laborde Professor of Cancer Research
Depts. of Medicine and Urology
Tulane Medical School
New Orleans, LA

Oliver Sartor, MD, discloses that he is a consultant for Algeta, Amgen, Bayer, Bellicum, Bristol-Myers Squibb, Celgene, Dendreon, Exelixis, GlaxoSmithKline, Johnson & Johnson, Medivation, OncoGenex, Sanofi-Aventis, and Takeda. He has also received research support from Algeta, AstraZeneca, Bayer, Cougar, Exelixis, Johnson & Johnson, Sanofi-Aventis, and Takeda. He intends to discuss non–FDA-approved or investigational use for products/devices.

Target Audience
This educational activity was directed toward medical oncologists, pathologists, geneticists, advanced practice oncology nurses, research nurses, clinical oncology pharmacists, genetic counselors, and other healthcare providers involved in the management of patients with solid tumors and interested in the use of molecular tumor biomarkers to help optimize patient care.

View Activity
Last modified: May 24, 2013